Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Breast Neoplasms 2Weight Loss 1Quality of Life 1Parasomnias 1Neoplasms 1Melanoma 1Depression 1Cachexia 1Breast Cancer - Female 1Anxiety Disorders 1

Interventions

pembrolizumab 51Ipilimumab 50Cyclophosphamide 43Nivolumab 41aldesleukin 30Interleukin-2 23Vemurafenib 20fludarabine 19Temozolomide 18fludarabine phosphate 15dabrafenib 15trametinib 12spartalizumab 10Radiotherapy 10Radiosurgery 10Dacarbazine 10CTLA-4 Antigen 10cobimetinib 9binimetinib 9poly ICLC 7encorafenib 7Paclitaxel 7atezolizumab 6Introns 6Biopsy 6montanide ISA 51 5Carboplatin 5epacadostat 4MART-1 Antigen 4Interferon alpha-2 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Melanoma × Melatonin × Clear all
NCT02190838 2019-11-25

Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone in Disseminated Melanoma

N.N. Petrov National Medical Research Center of Oncology

Phase 2 Terminated
57 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡